Corcept Therapeutics Officer Justin Frederick Gunn Files Initial Form 3

Overview

On October 5, 2026, Justin Frederick Gunn, President of Corcept Endocrinology at Corcept Therapeutics Inc ($CORT), submitted an initial statement of beneficial ownership on Form 3 with an effective date of October 1, 2026.

Beneficial Ownership Summary

• Common Stock (Direct): 12,191 shares, which include:
  • 141 unvested RSAs granted on December 1, 2025
  • 316 unvested RSAs granted on March 2, 2026
  • 405 unvested RSAs granted on June 1, 2026
  • 103 unvested RSAs granted on September 1, 2026
  • 6,000 unvested RSAs granted on September 1, 2026 (vesting quarterly over 4 years)

Derivative Holdings (Stock Options)

• 25,000 shares at an exercise price of $37.94 expiring August 1, 2034
• 25,000 shares at an exercise price of $60.58 expiring February 28, 2035
• 13,438 shares at an exercise price of $35.70 expiring February 27, 2036
• 8,959 shares at an exercise price of $35.70 expiring February 27, 2036

Market & Governance Impact

This filing represents standard baseline compliance reporting following Mr. Gunn's appointment/designation as a Section 16 reporting officer. As there are no open-market transactions, trading significance is assessed as Low.